{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:09:51Z","timestamp":1793196591485,"version":"4.5.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40265-023-01865-w","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T04:13:09Z","timestamp":1681877589000},"page":"639-643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Keverprazan Hydrochloride: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"issue":"12","key":"1865_CR1","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/apt.16959","volume":"55","author":"S Chen","year":"2022","unstructured":"Chen S, Liu D, Chen H, et al. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study. Aliment Pharmacol Ther. 2022;55(12):1524\u201333.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"1865_CR2","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1111\/jgh.16000","volume":"37","author":"ND Tan","year":"2022","unstructured":"Tan ND, Liu XW, Liu CX, et al. Efficacy of keverprazan for duodenal ulcer: a phase II randomized, double-blind, parallel-controlled trial. J Gastroenterol Hepatol. 2022;37(11):2060\u20136.","journal-title":"J Gastroenterol Hepatol"},{"key":"1865_CR3","unstructured":"National Medical Products Administration. The State Food and Drug Administration approved the marketing of Caprasen hydrochloride tablets. 15 Feb 2023. https:\/\/www.nmpa.gov.cn."},{"key":"1865_CR4","doi-asserted-by":"crossref","unstructured":"Jiangsu Carephar Pharmaceutical. Keverprazan hydrochloride tablets: Chinese prescribing information [Chinese]. 2023. https:\/\/www.nmpa.gov.cn. Accessed 21 Mar 2023.","DOI":"10.1007\/s40265-023-01865-w"},{"key":"1865_CR5","unstructured":"Fosun Pharma USA. Fosun Pharma and Carephar enter into a global collaboration to co-develop and exclusively commercialize China's first self-developed P-CAB product keverprazan hydrochloride. 19 Sep 2022. http:\/\/www.fosunpharma.com."},{"key":"1865_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejphar.2017.06.020","volume":"810","author":"CY Li","year":"2017","unstructured":"Li CY, Su M, Yan YY, et al. KFP-H008 blocks gastric acid secretion through inhibiting H(+)-K(+)-ATPase. Eur J Pharmacol. 2017;810:112\u20139.","journal-title":"Eur J Pharmacol"},{"key":"1865_CR7","unstructured":"Tan N, Miao X, Liao A, et al. The efficacy and safety of keverprazan (H008) in the treatment of duodenal ulcer: a multicentred, randomized, double-blind, active-control trial in China (abstract no. P0098). In: 30th United European Gastroenterology Week 2022."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01865-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01865-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01865-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T21:43:03Z","timestamp":1684446183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01865-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":7,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1865"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01865-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"19 April 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}